广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状

杨嘉璐; 罗燕芳; 单忍湖; 左志刚; 余振; 陈武农; 朱耀文; 李柳清; 骆诗韵; 叶咏欣; 张卓宇; 李瑞; 巨竞萌; 朱姗姗; 范佳画; 夏敏

doi:10.16462/j.cnki.zhjbkz.2021.10.011

文章导航 > 中华疾病控制杂志 > 2021 > 25(10): 1175-1179, 1230

杨嘉璐, 罗燕芳, 单忍湖, 左志刚, 余振, 陈武农, 朱耀文, 李柳清, 骆诗韵, 叶咏欣, 张卓宇, 李瑞, 巨竞萌, 朱姗姗, 范佳画, 夏敏. 广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状[J]. 中华疾病控制杂志, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

引用本文:

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

Citation:

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

引用本文:

Citation:

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状

doi: 10.16462/j.cnki.zhjbkz.2021.10.011

1.
510080 广州，中山大学公共卫生学院营养学系
2.
523076 东莞，南城社区卫生服务中心公共卫生办公室
3.
523381 东莞，茶山社区卫生服务中心预防保健部
4.
523381 东莞，茶山社区卫生服务中心全科医学部
5.
523165 东莞，东城社区卫生服务中心公共卫生办公室

基金项目:

国家重点研发计划 2017YFC0907100

详细信息

通讯作者:
夏敏，E-mail: xiamin@mail.sysu.edu.cn

中图分类号: R181.2
计量
- 文章访问数: 616
- HTML全文浏览量: 217
- PDF下载量: 51
- 被引次数: 0
出版历程
- 收稿日期: 2021-06-07
- 修回日期: 2021-09-15
- 网络出版日期: 2021-11-17
- 刊出日期: 2021-10-10

The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province

1.
Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
2.
Department of Public Health, Nancheng Community Health Service Center, Dongguan 523076, China
3.
Department of Prevention and Health, Chashan Community Health Service Center, Dongguan 523381, China
4.
Department of General Practice, Chashan Community Health Service Center, Dongguan 523381, China
5.
Department of Public Health, Dongcheng Community Health Service Center, Dongguan 523165, China

Funds:

National Key Research and Development Program of China 2017YFC0907100

More Information

Corresponding author: XIA Min, E-mail: xiamin@mail.sysu.edu.cn

摘要

摘要: 目的了解广东省东莞市30~79岁居民代谢相关脂肪性肝病(metabolic associated fatty liver disease, MAFLD) 的患病情况，探讨不同人群特征对MAFLD患病的影响。方法利用华南区域自然人群慢性病前瞻性队列研究在广东省东莞市的基线调查数据，包括体格检查、腹部超声检查和临床检验，共纳入8 670名研究对象。参考国际专家小组共识声明判断MAFLD患病情况。采用多因素Logistic回归分析模型分析男、女性MAFLD患病的影响因素。结果东莞市30~79岁居民MAFLD患病率为31.85%。男性各年龄段MAFLD患病率的差异无统计学意义(χ² =2.958, P=0.565)，女性患病率随年龄的增加而呈线性增长的趋势(χ_趋势²=81.429, P＜0.001)。MAFLD患病率随BMI、FPG、ALT、TG、TC、血尿酸(uric acid, UA)等代谢指标的升高而升高，随HDL-C的升高而降低。多因素Logistic回归分析模型结果显示年龄≥50岁的女性患MAFLD风险较高(OR=2.37, 95% CI: 1.74~3.23, P＜0.001)。结论东莞市30~79岁居民MAFLD患病率为31.85%，与BMI、FPG、TG、TC等代谢指标之间呈线性关联。年龄≥50岁可能是女性患MAFLD的危险因素。
- 代谢相关脂肪性肝病 /
- 患病 /
- 居民
Abstract: Objective To explore the prevalence of metabolic associated fatty liver disease (MAFLD) and the impact of different characteristics among residents aged 30 to 79 in Dongguan City of Guangdong Province. Methods Baseline data were collected in Dongguan City, Guangdong Province of South China Cohort, including physical examination, ultrasound, and laboratory tests. According to the inclusion and exclusion criteria, we included 8 670 participants and defined the status of MAFLD referred to the consensus statement of international experts. Multivariate Logistic regression analysis model was used to analyze the factors according to gender. Results The prevalence of MAFLD was 31.85% among residents aged 30 to 79 in Dongguan City. The prevalence was similar among males in different age groups (χ² =2.958, P=0.565), while it linearly increased with age in females (χ_trend²=81.429, P < 0.001). The prevalence showed a linear increase with BMI, FPG, ALT, TG, TC, uric acid (UA) while a linear decrease with HDL-C. The results of multivariate Logistic regression analysis model showed that females ≥50 years old had a higher risk of MAFLD (OR=2.37, 95% CI: 1.74~3.23, P < 0.001). Conclusions The prevalence of MAFLD was 31.85% among residents aged 30 to 79 in Dongguan City, and there was a linear association between the prevalence of MAFLD and various metabolic indices including BMI, FPG, TG, and TC. Age ≥50 years old may be a risk factor of MAFLD in females.
- Metabolic associated fatty liver disease /
- Prevalence /
- Residents

HTML全文

图 1 2018―2019年广东省东莞市不同特征调查对象的MAFLD患病率

Figure 1. The prevalence of MAFLD according to various characteristics among participants in Dongguan City, Guangdong Province from 2018 to 2019

下载: 全尺寸图片幻灯片

表 1 2018―2019年广东省东莞市30~79岁调查对象的基本特征[n(%)]

Table 1. Basic characteristics of participants aged 30 to 79 in Dongguan City, Guangdong Province from 2018 to 2019 [n(%)]

变量	总人群(N=8 670)	男性(n=3 525)	女性(n=5 145)	t/t’/Z/χ²值	P值
年龄[(x±s), 岁]	65.33±9.34	65.55±9.42	65.18±9.28	-1.847	0.065
高血压				4.436	0.035
有	3 947(46.07)	1 551(44.70)	2 396(47.01)
无	4 620(53.93)	1 919(55.30)	2 701(52.99)
超重/肥胖				0.144	0.705
是	5 498(63.41)	2 227(63.18)	3 271(63.58)
否	3 172(36.59)	1 298(36.82)	1 874(36.42)
糖尿病				2.075	0.150
是	686(8.10)	296(8.62)	390(7.75)
无	7 783(91.90)	3 139(91.38)	4 644(92.25)
代谢功能失调				369.934	＜0.001
是	5 618(64.80)	1 864(52.88)	3 754(72.96)
否	3 052(35.20)	1 661(47.12)	1 391(27.04)
WC[(x±s), cm]	85.49±9.48	86.55±9.09	84.76±9.68	-8.704	＜0.001
BMI[(x±s), kg/m²]	24.30±3.47	24.11±3.21	24.42±3.63	4.108	＜0.001
SBP[(x±s), mm Hg]	137.31±19.35	136.19±18.13	138.07±20.11	4.499	＜0.001
DBP[(x±s), mm Hg]	81.05±10.66	81.96±10.72	80.43±10.57	-6.537	＜0.001
FPG[M(P₂₅, P₇₅), mmol/L]	4.98(4.57, 5.57)	4.99(4.57, 5.59)	4.97(4.57, 5.56)	-0.855	0.393
ALT[M(P₂₅, P₇₅), IU/L]	20.00(15.00, 26.10)	21.00(16.00, 28.00)	19.00(14.90, 25.00)	-10.882	＜0.001
AST[M(P₂₅, P₇₅), IU/L]	22.00(18.80, 26.31)	22.00(19.00, 27.00)	22.00(18.43, 26.00)	-3.710	＜0.001
TBIL[M(P₂₅, P₇₅), μmol/L]	13.20(10.60, 16.59)	14.20(11.20, 17.80)	12.70(10.20, 15.70)	-14.094	＜0.001
TG[M(P₂₅, P₇₅), mmol/L]	1.38(0.99, 2.02)	1.33(0.94, 1.93)	1.43(1.02, 2.06)	-5.909	＜0.001
TC[(x±s), mmol/L]	5.28±1.08	5.04±1.04	5.45±1.07	17.330	＜0.001
HDL-C[(x±s), mmol/L]	1.37±0.34	1.27±0.32	1.43±0.33	23.190	＜0.001
LDL-C[(x±s), mmol/L]	3.26±0.92	3.16±0.90	3.32±0.93	8.264	＜0.001
血尿素[M(P₂₅, P₇₅), mmol/L]	5.44(4.57, 6.51)	5.57(4.67, 6.67)	5.37(4.51, 6.40)	-6.590	＜0.001
血肌酐[M(P₂₅, P₇₅), μmol/L]	72.00(61.00, 85.00)	85.00(75.00, 97.00)	64.00(56.90, 73.00)	-54.159	＜0.001
UA[(x±s), μmol/L]	364.69±98.50	401.51±96.88	339.53±91.43	-29.510	＜0.001

下载: 导出CSV

表 2 2018―2019年广东省东莞市不同性别、年龄调查对象MAFLD患病率

Table 2. The prevalence of MAFLD according to gender and age group among participants in Dongguan City, Guangdong Province from 2018 to 2019

年龄组(岁)	性别	总人数	患病人数	患病率(%)	χ²值	P值
30~＜40	男	91	25	27.47	6.484	0.011
	女	131	18	13.74
40~＜50	男	225	66	29.33	20.797	＜0.001
	女	337	46	13.65
50~＜60	男	286	77	26.92	0.207	0.649
	女	398	101	25.38
60~＜70	男	1 620	448	27.65	65.079	＜0.001
	女	2 584	1 030	39.86
70~79	男	1 303	329	25.25	44.133	＜0.001
	女	1 695	621	36.64

下载: 导出CSV

表 3 2018―2019年广东省东莞市男、女性MAFLD患病的多因素Logistic回归分析

Table 3. Multivariate Logistic regression for MAFLD according to gender among participants in Dongguan City, Guangdong Province from 2018 to 2019

自变量	男性			女性
自变量	β值	OR(95% CI)值	P值	β值	OR(95% CI)值	P值
年龄≥50(岁)	0.218	1.24(0.92~1.69)	0.161	0.862	2.37(1.74~3.23)	＜0.001
超重/肥胖	1.750	5.75(4.28~7.34)	＜0.001	1.547	4.70(3.86~5.71)	＜0.001
糖尿病	0.815	2.26(1.70~3.01)	＜0.001	0.784	2.19(1.71~2.81)	＜0.001
WC异常	0.952	2.59(2.15~3.13)	＜0.001	0.897	2.45(1.98~3.04)	＜0.001
血压异常	0.223	1.25(1.02~1.54)	0.035	0.207	1.23(1.04~1.45)	0.013
TG异常	0.871	2.39(1.99~2.87)	＜0.001	0.925	2.52(2.18~2.92)	＜0.001
HDL-C异常	0.075	1.08(0.88~1.33)	0.477	0.346	1.41(1.22~1.63)	＜0.001
ALT异常	0.655	1.93(1.17~3.17)	0.010	0.960	2.61(1.98~3.44)	＜0.001
高尿酸血症	0.341	1.41(1.18~1.68)	＜0.001	0.537	1.71(1.49~1.97)	＜0.001

下载: 导出CSV

参考文献(22)

[1]	Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461. DOI: 10.1016/j.jhep.2021.05.003.
[2]	Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[3]	Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. DOI: 10.1053/j.gastro.2019.11.312.
[4]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[5]	Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy[J]. Chin Med J (Engl), 2020, 134(1): 8-19. DOI: 10.1097/CM9.0000000000001263.
[6]	Nabi O, Lacombe K, Boursier J, et al. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study[J]. Gastroenterology, 2020, 159(2): 791-793. DOI: 10.1053/j.gastro.2020.04.048.
[7]	Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
[8]	Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management[J]. Intern Med J, 2020, 50(9): 1038-1047. DOI: 10.1111/imj.14709.
[9]	Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study[J]. BMC Gastroenterol, 2021, 21(1): 212. DOI: 10.1186/s12876-021-01782-w.
[10]	Li H, Guo M, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818. DOI: 10.3390/ijerph17061818.
[11]	Liu D, Shen Y, Zhang R, et al. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China[J]. J Gastroenterol Hepatol, 2020, 36(6): 1670-1678. DOI: 10.1111/jgh.15320.
[12]	Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
[13]	Lai X, Yang L, Legare S, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort[J]. Int J Cardiol, 2016, 224: 299-304. DOI: 10.1016/j.ijcard.2016.09.035.
[14]	Wong WV, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2161-2171. DOI: 10.1016/j.cgh.2020.10.046.
[15]	Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol, 2007, 13(47): 6419-6424. DOI: 10.3748/wjg.v13.i47.6419.
[16]	Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography[J]. Gut, 2012, 61(3): 409-415. DOI: 10.1136/gutjnl-2011-300342.
[17]	Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 1): 138-143. DOI: 10.1111/j.1440-1746.2005.04086.x.
[18]	Yoneda M, Thomas E, Sumida Y, et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60(5): 1792. DOI: 10.1002/hep.27097.
[19]	Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(4): 1406-1414. DOI: 10.1002/hep.26761.
[20]	Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
[21]	Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4): 637-653. DOI: 10.1016/j.bpg.2014.07.008.
[22]	Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis[J]. Diabetes Care, 2018, 41(2): 372-382. DOI: 10.2337/dc17-1902.